Melanoma Coverage from Every Angle

FDA Fast Track Designation: Tebentafusp in Metastatic Uveal Melanoma

By: Sarah Jackson
Posted: Monday, April 15, 2019

The U.S. Food and Drug Administration recently granted Fast Track designation for tebentafusp in the treatment of patients who are HLA-A*0201–positive with previously untreated, metastatic uveal melanoma. Tebentafusp has previously been granted Orphan Drug designation for melanoma by the FDA.

Tebentafusp is being studied in the IMCgp100-202 trial ( identifier NCT03070392), a 2:1 randomized study of tebentafusp compared with investigator’s choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201–positive adult patients with previously untreated metastatic uveal melanoma. The primary endpoint is a comparison of overall survival.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.